Optum Pharmacy 706, INC.
Optum Pharmacy 706, INC. was paid $25.32M by Medicaid between Jan 2018 and Sep 2024, across 19 billing codes. Its largest line is J2323, Injection, natalizumab, 1 mg — 45% of everything it billed.
LONG ISLAND CITY, NY 11101
Next to other Pharmacy providers in New York
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,526 | $4.55M | |
| 2019 | 2,747 | $5.09M | |
| 2020 | 2,264 | $4.69M | |
| 2021 | 2,034 | $4.57M | |
| 2022 | 1,492 | $4.23M | |
| 2023 | 748 | $1.61M | |
| 2024incomplete | 410 | $582K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J2323 | Injection, natalizumab, 1 mg | 45% | 1,658 | 1,540 | $11.38M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 28% | 5,781 | 5,687 | $7.18M |
| J1726 | Injection, hydroxyprogesterone caproate, (makena), 10 mg | 12% | 1,101 | 986 | $3.16M |
| J0897 | Injection, denosumab, 1 mg | 5.1% | 1,003 | 980 | $1.29M |
| J2315 | Injection, naltrexone, depot form, 1 mg | 2.8% | 521 | 499 | $699K |
| J0517 | Injection, benralizumab, 1 mg | 1.6% | 87 | 81 | $416K |
| Q9991 | Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg | 1.3% | 203 | 190 | $320K |
| J7324 | Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | 1.0% | 95 | 95 | $259K |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | <1% | 185 | 168 | $239K |
| Q9992 | Injection, buprenorphine extended-release (sublocade), greater than 100 mg | <1% | 88 | 88 | $141K |
| J1729 | Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg | <1% | 41 | 40 | $89K |
| J3590 | Unclassified biologics | <1% | 12 | 12 | $87K |
7 more codes
| J2182 | Injection, mepolizumab, 1 mg | <1% | 21 | $40K |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 223 | $23K |
| Q0512 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period | 0% | 460 | $0.00 |
| J7517 | Mycophenolate mofetil, oral, 250 mg | 0% | 38 | $0.00 |
| Q0511 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period | 0% | 305 | $0.00 |
| J7518 | Mycophenolic acid, oral, 180 mg | 0% | 124 | $0.00 |
| J7507 | Tacrolimus, immediate release, oral, 1 mg | 0% | 275 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.